Table 2.
A list of SARS-CoV-2 VLP vaccines currently under clinical trial.
| Vaccine | Antigens and Adjuvants |
Manufacturer/Responsible Party | Clinical Trial Phase and Identifier |
|---|---|---|---|
| LYB001 | S protein RBD; alum adjuvant |
Yantai Patronus Biotech Co., Ltd. | Phase 2/3 NCT05125926, NCT05137444 |
| VBI-2902a | Pre-fusion stabilized S protein; alum adjuvant |
Variation Biotechnologies Inc., | Phase 1/2 NCT04773665 |
| SARS-CoV-2 VLP (unnamed) |
All structural proteins of the SARS-CoV-2 | Scientific and Technological Research Council of Turkey |
Phase 2 NCT04962893 |
| ABNCoV2 | SARS-CoV-2 S RBD; MF49 adjuvant |
Bavarian Nordic | Phase 3 NCT05329220 |
| CoVLP | Modified pre-fusion stabilized S protein; AS03 adjuvant |
Medicago Inc., and GlaxoSmithKline |
Phase 3 NCT04636697 |
| Spike-ferritin nanoparticle (SpFN) |
Spike-ferritin; ALFQ adjuvant |
U.S. Army Medical Research and Development Command | Phase 1 NCT04784767 |